Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease

October 1992
OTA-BP-H-104
NTIS order #PB93-101723
Foreword

The effort to discover and develop new pharmaceuticals is a risky and costly enterprise. For diseases that affect few patients, the barriers to development maybe especially great, since the drugs’ small markets may make it difficult for firms to recoup their initial research and development investments. The Federal Government has sought to reduce these barriers through incentives first adopted in the Orphan Drug Act of 1983 (Public Law 97-414). The transfer of technology from Federal laboratories such as the National Institutes of Health to the pharmaceutical industry can also reduce the cost and risk of drug development for firms. Although such incentives may result in important new therapies, their price to patients and insurers may still be high.

As part of our assessment, Government Policies and Pharmaceutical Research and Development, requested by the House Committee on Energy and Commerce and its Subcommittee on Health and the Environment and the Subcommittee on Antitrust, Monopolies, and Business Rights of the Senate Committee on the Judiciary, OTA commissioned researchers at Stanford University to examine the development and provision of alglucerase, an important new treatment for Gaucher disease. Gaucher disease is a rare inherited disorder in which the body lacks an enzyme necessary to break down fats. This background paper describes the development of alglucerase, illustrates the role that both the Federal Government and private sector can have in making new therapies available for orphan diseases, and lays out some of the tradeoffs that can exist between developing new medical technologies and controlling health care costs.
OTA Staff—Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease

Roger C. Herdman, Assistant Director
Health and Life Sciences Division

Clyde J. Behney, Health Program Manager

Project Staff

Judith L. Wagner, Project Director,
Government Policies and Pharmaceutical Research and Development

Michael E. Gluck, Study Director

Timothy Brogan, Research Assistant
Arna M. Lane, Research Assistant

Administrative Staff

Marian Grochowski, Office Administrator

Eileen Murphy, P.C. Specialist
Kimberly Holmlund, Word Processing Specialist

Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease

Background Paper

This background paper was prepared as part of OTA’s assessment of Government Policies and Pharmaceutical Research and Development.

Prepared by:

Alan M. Garber
Palo Alto Department of Veterans Affairs Medical Center
and Stanford University

Ann E. Clarke
Stanford University

Dana P. Goldman
Stanford University

Michael E. Gluck
Office of Technology Assessment
U.S. Congress
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCBS</td>
<td>Blue Cross and Blue Shield</td>
</tr>
<tr>
<td>CHAMPUS</td>
<td>Civilian Health and Medical Program of the Uniformed Services</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HCFA</td>
<td>Health Care Financing Administration</td>
</tr>
<tr>
<td>HCPCS</td>
<td>HCFA's Common Procedure Coding System</td>
</tr>
<tr>
<td>HMO</td>
<td>health maintenance organization</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>NDA</td>
<td>New Drug Application</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>ODA</td>
<td>Orphan Drug Act</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>research and development</td>
</tr>
<tr>
<td>SSA</td>
<td>Social Security Administration</td>
</tr>
</tbody>
</table>